Tagged with Pharma

Portugal Carla Benedito, general manager of Shire Portugal, provides useful insight into the rare diseases landscape in Portugal. Carla discusses market access models for innovative and rare treatments, encouraging dialogue between industry and government, and the touching nature of working for a pharmaceutical company that knows all of its patients by…

UK Confirming Eisai’s commitment to keeping its EMEA headquarters in the UK, Gary Hendler, chairman and CEO EMEA, and Nick Burgin, COO and president of global value and access stress how the company is looking at Brexit as a glass half full. Eisai views Brexit as an opportunity to bring with…

Europe The top spenders on pharma R&D in Europe for 2015 were Switzerland – which spent over EUR 6.5 billion – followed by Germany – which spent EUR 6.2 billion – and the UK – which spent EUR 5.8 billion.

Cannabis While many Canadian medical cannabis outfits cover the entire value chain, from research and development through to manufacturing and distribution, others – such as Canopy Health and Tetra Bio-Pharma – are taking their cues from the biotechnology industry and strictly focusing on clinical trials.   I believe that across the…

Pharma In May 2018, PharmaBoardroom’s readers were asked what they felt were the biggest new sources of disruption to the traditional pharma industry today. Options included 3D Bioprinting, blockchain storage, genomics and artificial intelligence. 3D Bioprinting As Figure 1 (below) shows, 11 percent of our survey respondents felt that 3D bioprinting…

Portugal Olga Insua, the new American general manager for Novo Nordisk Portugal, fresh off the plane from Spain, provides an exclusive insight into her impressive career at the company, the blending of business practices from Europe and New Jersey, and why patients should always be at the center of every process.…

Portugal Antonio Leão discusses Lilly Portugal’s sustained growth record in recent years, its ambition to introduce two new innovative treatments to the market every year until 2022, and their empowering approach when tackling market access hurdles. In suggesting improvements to the predictability of the pharmaceutical framework, Leão, soon to reach 30…

Malta Marius Calleja, general manager of Maltese contract manufacturer, Starpharma, discusses the company’s current growth strategy and how Starpharma can capitalize on the emergent medical cannabis niche.       Even though you only started as general manager six months ago, can you describe the evolution of Starpharma over the years?…

Malta Andrew Corrieri, founder and CEO at Pharmaconsulta Ltd, tells the story of how he founded his consultancy, as well as the key expertise he can bring to its clients. Moreover, as one of the key experts in the industry, Corrieri takes the time to highlight the key advantages of doing…

Portugal Cristina Campos is well known on the Portuguese pharmaceutical circuit, directing the affiliate of market leader, Novartis, and holding a position as vice-president at APIFARMA, the Portuguese Pharmaceutical Association. In her second meeting with PharmaBoardroom, Campos discusses the Portuguese ‘talent machine’, an exciting new portfolio with incredibly strong launches on…

Europe The most valuable pharma markets in Europe for 2015. Germany leads the way, followed by France, Italy and the UK. For more pharma facts and figures, click here.

China One of the more eye-catching and ambitious initiatives to come out of last March’s National People’s Congress, Premier Li Keqiang’s grand vision for the cultivation of a globally competitive cluster of metropolises and “innovation super-hub” in China’s Greater Bay Area (GBA), is now starting to take shape as the country…